B. Masquelier

发表

Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced Patients

B. Masquelier, D. Breilh, D. Neau, 2002, Antimicrobial Agents and Chemotherapy.

European guidelines on the clinical management of HIV-1 tropism testing.

A. Wensing, H. Walter, R. Kaiser, 2011, The Lancet. Infectious diseases.

Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism.

V. Calvez, B. Masquelier, J. Izopet, 2011, The Journal of antimicrobial chemotherapy.

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

V. Calvez, C. Charpentier, J. Pawlotsky, 2015, PloS one.

Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study

C. Charpentier, B. Masquelier, J. Izopet, 2010, Antimicrobial Agents and Chemotherapy.

Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine

V. Calvez, F. Ceccherini‐Silberstein, B. Masquelier, 2011, ChemMedChem.

An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients

B. Masquelier, J. Ragnaud, M. Dupon, 2006 .

HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase.

F. Brun-Vézinet, B. Masquelier, L. Deforges, 1992, Journal of virological methods.

Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load

D. Pillay, B. Masquelier, F. Dabis, 2006, Antiviral therapy.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

K. Metzner, M. Kozal, R. Paredes, 2011, JAMA.

The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy

D. Pillay, G. Poggensee, B. Masquelier, 2006, AIDS.

Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection

M. Wainberg, M. Ntemgwa, B. Brenner, 2009, Antimicrobial Agents and Chemotherapy.

Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

H. Walter, R. Kaiser, K. Korn, 2010, Journal of the International AIDS Society.

Multicentric Castleman disease: Use of HHV8 viral load monitoring and positron emission tomography during follow-up

B. Masquelier, P. Morlat, F. Bonnet, 2007, Leukemia & lymphoma.

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

B. Masquelier, F. Dabis, C. Rouzioux, 2007, International journal of epidemiology.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

V. Calvez, C. Charpentier, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Acquired immunodeficiency syndrome-associated Kaposi's sarcoma and human herpesvirus 8 DNA detection in serial peripheral blood mononuclear cell samples.

B. Masquelier, J. Ragnaud, M. Dupon, 1997, Research in virology.

Multicenter evaluating of a commercially available PCR assay for diagnosing enterovirus infection in a panel of cerebrospinal fluid specimens

B. Masquelier, H. Fleury, J. Puel, 1996, Journal of clinical microbiology.

Asymmetric Periflexural Exanthem of Childhood: Microbiologic Case‐Control Study

B. Masquelier, P. Bioulac-Sage, A. Taïeb, 2000, Pediatric dermatology.

Primary Resistance to Enfuvirtide (T20) in recently HIV-1 Infected, Antiretroviral-Naive Patients from the ANRS Aquitaine Cohort

B. Masquelier, J. Ragnaud, H. Fleury, 2007, Antiviral therapy.

Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures.

B. Masquelier, D. Neau, J. Ragnaud, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

L. Stuyver, B. Masquelier, H. Fleury, 2010, PloS one.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

A. Mocroft, H. Günthard, R. Paredes, 2010, Archives of internal medicine.

Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.

R. Salamon, B. Masquelier, F. Dabis, 2002, AIDS.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

A. Mocroft, H. Günthard, D. Podzamczer, 2013, The Journal of infectious diseases.

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.

B. Masquelier, H. Fleury, O. Cosnefroy, 2010, The Journal of antimicrobial chemotherapy.

HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

V. Calvez, P. Harrigan, B. Masquelier, 2012, Antimicrobial Agents and Chemotherapy.

Further characterization of HIV-1 isolates from Ho Chi Minh City, Vietnam.

B. Masquelier, H. Fleury, T. V. Nguyen, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases.

B. Masquelier, L. Vaillant, P. Courville, 1999, The American journal of surgical pathology.

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

V. Calvez, F. Ceccherini‐Silberstein, C. Katlama, 2011, The Journal of antimicrobial chemotherapy.

HIV‐1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation

B. Masquelier, J. Ragnaud, M. Dupon, 2006, HIV medicine.

Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors.

R. Salamon, B. Masquelier, J. Moatti, 2001 .

Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV‐Infected Patients Initiating Protease Inhibitors

R. Salamon, B. Masquelier, J. Moatti, 2001, Journal of acquired immune deficiency syndromes.

Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8.

B. Masquelier, H. Fleury, F. Neipel, 1999, Virology.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

A. Mocroft, D. Podzamczer, A. Phillips, 2012, The Lancet. Infectious diseases.

Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe

A. Mocroft, D. Podzamczer, A. Phillips, 2011, Journal of acquired immune deficiency syndromes.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

B. Masquelier, D. Breilh, D. Neau, 2010, The Journal of antimicrobial chemotherapy.

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2001, Antimicrobial Agents and Chemotherapy.

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy

Rodolphe Thiébaut, François Dabis, Philippe Morlat, 2008, AIDS.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients

V. Calvez, H. Günthard, S. Yerly, 2006, AIDS.

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Philippe Flandre, Vincent Calvez, Jacques Izopet, 2008, Antimicrobial Agents and Chemotherapy.

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease

B. Masquelier, H. Fleury, C. Rouzioux, 1996 .

Human herpesvirus 8 variants in Venezuelan patients with AIDS-related Kaposi sarcoma.

B. Masquelier, H. Fleury, D. Hernåndez, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors?

B. Masquelier, J. Ragnaud, M. Dupon, 1998, The Journal of infectious diseases.

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure

B. Masquelier, D. Neau, P. Morlat, 2014, PloS one.

Minority drug-resistant HIV-1 variants: transmission and response to antiretroviral therapy

B. Masquelier, 2009 .

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2007, Antiviral therapy.

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2003, AIDS.

HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs.

B. Masquelier, H. Fleury, P. Roques, 2003, AIDS research and human retroviruses.

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.

David Dunn, Kholoud Porter, Rodolphe Thiébaut, 2011, The Lancet. Infectious diseases.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2013, The Journal of antimicrobial chemotherapy.

French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002

F. Brun-Vézinet, P. André, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study Group.

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2000, Journal of acquired immune deficiency syndromes.

In vitro assays show a dissociation of reverse transcriptase activity and core antigen (p24) production in two HIV-1 isolates from a patient receiving long-term treatment with zidovudine (ZDV).

B. Masquelier, H. Fleury, J. Pellegrin, 1991, Journal of acquired immune deficiency syndromes.

Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.

B. Masquelier, H. Fleury, E. Lazaro, 2005, AIDS research and human retroviruses.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France

C. Delaugerre, B. Masquelier, C. Rouzioux, 2009, AIDS.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study.

R. Salamon, B. Masquelier, F. Dabis, 2003, AIDS research and human retroviruses.

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

R. Salamon, F. Brun-Vézinet, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2010, The Journal of antimicrobial chemotherapy.

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group.

B. Masquelier, C. Rouzioux, D. Dormont, 1996, JAMA.

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes

V. Calvez, C. Katlama, B. Masquelier, 2009, Antimicrobial Agents and Chemotherapy.

Heterosexual transmission of Kaposi's sarcoma-associated herpes virus between two patients developing AIDS-Kaposi's sarcoma.

B. Masquelier, M. Dupon, H. Fleury, 2000, AIDS.

Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.

B. Masquelier, H. Fleury, C. Rouzioux, 2001 .

Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.

B. Masquelier, D. Neau, J. Ragnaud, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.

C. Charpentier, B. Masquelier, F. Raffi, 2011, The Journal of antimicrobial chemotherapy.

Zidovudine Resensitization and Dual HIV-1 Resistance to Zidovudine and Lamivudine in the Delta Lamivudine Roll-Over Study

F. Brun-Vézinet, B. Masquelier, J. Izopet, 1998, Antiviral therapy.

Prevalence of HIV-1 Drug Resistance in Treated Patients: A French Nationwide Study

F. Brun-Vézinet, C. Delaugerre, S. Yerly, 2007, Journal of acquired immune deficiency syndromes.

Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR.

B. Masquelier, H. Fleury, P. Pinson, 2007, AIDS research and human retroviruses.

Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data.

B. Masquelier, H. Fleury, E. Lazaro, 2006, AIDS research and human retroviruses.

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

K. Metzner, A. d’Arminio Monforte, A. Schultze, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

V. Calvez, C. Katlama, B. Masquelier, 2012, PloS one.

First observation of HIV type 1 drug resistance mutations in Algeria.

B. Masquelier, H. Fleury, P. Pinson, 2008, AIDS research and human retroviruses.

Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.

B. Masquelier, M. Dupon, F. Raffi, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients

F. Brun-Vézinet, B. Masquelier, D. Costagliola, 2003, Antiviral therapy.

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

N. Pantazis, B. Masquelier, A. Monforte, 2013, PloS one.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.

C. Delaugerre, S. Yerly, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.

R. Salamon, B. Masquelier, F. Dabis, 2007, AIDS research and human retroviruses.

High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2011, Antiviral therapy.

Presence of CRF09_cpx and complex CRF02_AG/CRF09_cpx recombinant HIV type 1 strains in Côte d'Ivoire, West Africa.

John Nkengasong, Martine Peeters, Monica Nolan, 2005, AIDS research and human retroviruses.

Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003

D. Pillay, G. Poggensee, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

V. Calvez, C. Charpentier, B. Masquelier, 2014, The Journal of antimicrobial chemotherapy.

Repeated HIV‐1 resistance genotyping external quality assessments improve virology laboratory performance

V. Calvez, F. Brun-Vézinet, C. Delaugerre, 2006, Journal of medical virology.

Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study

V. Calvez, B. Masquelier, D. Costagliola, 2001, AIDS.

Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism

V. Calvez, B. Masquelier, J. Izopet, 2011, Antimicrobial Agents and Chemotherapy.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

V. Calvez, C. Delaugerre, S. Yerly, 2013, International journal of antimicrobial agents.

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2002, The Journal of infectious diseases.

Detection of Human Immunodeficiency Virus Type 1 Antiretroviral Resistance Mutations by High-Density DNA Probe Arrays

B. Masquelier, H. Fleury, G. Vernet, 2004, Journal of Clinical Microbiology.

Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions.

D. Pillay, B. Masquelier, C. Balotta, 2009, The Journal of infectious diseases.

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.

V. Calvez, C. Charpentier, C. Delaugerre, 2012, The Journal of antimicrobial chemotherapy.

Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients

V. Calvez, C. Charpentier, C. Delaugerre, 2009, Antimicrobial Agents and Chemotherapy.

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV‐1‐infected patients: A French nationwide study

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2005, Journal of medical virology.

Clinically relevant interpretation of genotype for resistance to abacavir

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2003, AIDS.

Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A

M. Laguerre, B. Masquelier, D. Neau, 2011, Antimicrobial Agents and Chemotherapy.

Structure analysis of HIV-1 IN Y143C/R Raltegravir resistance mutation in association

C. Calmels, H. Fleury, M. Laguerre, 2011 .

Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by Nevirapine in Patients With Suppressed Plasma HIV‐1 RNA

B. Masquelier, D. Neau, G. Chêne, 2001, Journal of acquired immune deficiency syndromes.

HIV Type-1 Transmission Dynamics in Recent Seroconverters: Relationship with Transmission of drug Resistance and Viral Diversity

B. Masquelier, D. Neau, P. Morlat, 2008, Antiviral therapy.

Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2006, AIDS.

Emerging Mutations and Associated Factors in Patients Displaying Treatment Failure on An Etravirine-Containing Regimen

V. Calvez, C. Delaugerre, B. Masquelier, 2012, Antiviral therapy.

HIV-1 transmission during scintigraphy

B. Masquelier, M. Dupon, H. Fleury, 2003, The Lancet.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

S. Yerly, B. Masquelier, H. Fleury, 2013, The Journal of antimicrobial chemotherapy.

R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen

B. Masquelier, F. Raffi, B. Spire, 2003, Antimicrobial Agents and Chemotherapy.

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

B. Masquelier, H. Fleury, F. Raffi, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

C. Fagard, B. Masquelier, D. Breilh, 2009, The Journal of antimicrobial chemotherapy.

Surveillance of HIV type 1 drug resistance among naive patients from Venezuela.

B. Masquelier, H. Fleury, P. Pinson, 2009, AIDS research and human retroviruses.

Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.

B. Masquelier, M. Dupon, F. Dabis, 2006, Journal of Clinical Virology.

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

V. Calvez, C. Delaugerre, S. Yerly, 2008, The Journal of antimicrobial chemotherapy.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

A. Mocroft, H. Günthard, R. Paredes, 2010, Archives of internal medicine.

Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy

B. Masquelier, O. Lambotte, J. Thèze, 2007, AIDS.

Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection

M. Wainberg, M. Ntemgwa, B. Brenner, 2009, Antimicrobial Agents and Chemotherapy.

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

B. Masquelier, D. Neau, J. Ragnaud, 2001 .

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy

B. Masquelier, D. Neau, P. Morlat, 2008, AIDS.